Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 10/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30289964 | 0.94 | NOTUM (0.61) | NOTUMALDH1A1L3MBTL1KMT2ATSHR | |
| SCHEMBL7395744 | 0.94 | NOTUM (0.61) | NOTUMALDH1A1L3MBTL1KMT2ATSHR | |
| SCHEMBL11498426 | 0.81 | NOTUM (0.53) | NOTUMKMT2ATSHRLMNAPDK2 | |
| SCHEMBL4276979 | 0.78 | NOTUM (0.70) | NOTUMKMT2ATSHRNPC1RAB9A | |
| SCHEMBL3624979 | 0.77 | NOTUM (0.59) | NOTUMKMT2ATSHRLMNAPDK2 | |
| SCHEMBL24026539 | 0.76 | NOTUM (0.48) | NOTUMALDH1A1L3MBTL1KMT2ATSHR | |
| SCHEMBL3283250 | 0.76 | NOTUM (0.66) | NOTUMALDH1A1KMT2ATSHRNPC1 | |
| SCHEMBL4752346 | 0.74 | NOTUM (1.00) | NOTUMALDH1A1KMT2ATSHRLMNA | |
| Fenadiazole SCHEMBL555484 | 0.74 | NOTUM (0.61) | NOTUMALDH1A1KMT2ATSHRLMNA | |
| SCHEMBL21061962 | 0.74 | NOTUM (0.61) | NOTUMKMT2ATSHRLMNAPDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578736-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL-PHENYLAMINE DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
| WO-2004056789-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL PHENYLAMINE DERIVATES | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004186-A1 | MEK inhibiting compounds | MAPK1, MAP3K1, MAPK3 | NOTUM 3478/4885ALDH1A1 1628/4885L3MBTL1 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.